Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumour immunity regulated by aberrant ERBB family signalling.

Nature reviews. Cancer - 1 Mar 2021

Kumagai Shogo, Koyama Shohei, Nishikawa Hiroyoshi

Abstract excerpt

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents against these signalling pathways exhibit robust clinical efficacy, but patients inevitably experience acquired resistance to these molecular-targeted therapies. Although cancer immunotherapies, including immune checkpoint inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ErbB Receptors
Share to Immune Checkpoint Inhibitors
Share to Major Histocompatibility Complex

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Signal Transduction

Share to Tumor Microenvironment

Source

Identifiers

PMID: 33462501
DOI: 10.1038/s41568-020-00322-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumour immunity regulated by aberrant ERBB family signalling.PMID 33462501Read ↗

ErbB/HER family in cancer immunology: therapeutic advances and mechanismsSemantic proximity Read ↗

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.Semantic proximity Read ↗

Genetic Dysregulation of Immunologic and Oncogenic Signaling Pathways Associated with Tumor-intrinsic Immune Resistance: A Molecular Basis for Combination Targeted Therapy-Immunotherapy for CancerSemantic proximity Read ↗

Targeting ErbB receptor signaling: A pan-ErbB approach to cancerSemantic proximity Read ↗

ErbB-targeted therapeutic approaches in human cancerSemantic proximity Read ↗

The Role of ERBB4 Mutations in the Prognosis of Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity Read ↗

ErbB receptors: from oncogenes to targeted cancer therapiesSemantic proximity Read ↗

The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillanceSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Effector mechanisms of therapeutic antibodies against ErbB receptors.Semantic proximity Read ↗

EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy.Semantic proximity Read ↗

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.